Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 1/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | PLA2G2A | P14555 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 4/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4384519 | 0.96 | FAAH (0.48) | FAAHKCNH2MEN1KMT2ANPC1 | |
| SCHEMBL4088721 | 0.94 | KCNH2 (0.48) | FAAHKCNH2MEN1KMT2ANPC1 | |
| SCHEMBL4089993 | 0.94 | KMT2A (0.48) | FAAHKCNH2MEN1KMT2ANPC1 | |
| SCHEMBL4097912 | 0.93 | FAAH (0.51) | FAAHMEN1KMT2ASMN1; SMN2USP2 | |
| SCHEMBL4098796 | 0.92 | KMT2A (0.46) | FAAHKCNH2MEN1KMT2ANPC1 | |
| SCHEMBL4384405 | 0.92 | FAAH (0.51) | FAAHMEN1KMT2ASMN1; SMN2USP2 | |
| SCHEMBL4096113 | 0.91 | KCNH2 (0.48) | FAAHKCNH2MEN1KMT2ANPC1 | |
| SCHEMBL3007578 | 0.91 | FAAH (0.51) | FAAHMEN1KMT2ANPC1RAB9A | |
| SCHEMBL4089939 | 0.90 | MEN1 (0.45) | FAAHKCNH2MEN1KMT2ANPC1 | |
| SCHEMBL4100737 | 0.89 | MAPT (0.49) | KCNH2SMN1; SMN2MAPTRXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2610244-A1 | Indole compounds | Ironwood Pharmaceuticals, Inc. (US) | 2013-07-03 | — | — | EP | disclosed |
| CN-102850324-A | Indole compounds | MICROBIA INC | 2013-01-02 | — | — | CN | disclosed |
| US-20090118503-A1 | FAAH INHIBITORS | IRONWOOD PHARMACEUTICALS, INC. | 2009-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118503-A1 | FAAH INHIBITORS | FAAH, FAAH2, CNR2 | FAAH 1/4885KCNH2 1943/4885MEN1 4573/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.